AstraZeneca to buy remaining stake in Caelum for $500m
With the transaction, the British drugmaker will obtain Caelum’s potential fibril-reactive monoclonal antibody (mAb) CAEL-101 for the treatment…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
30 Sep 21
With the transaction, the British drugmaker will obtain Caelum’s potential fibril-reactive monoclonal antibody (mAb) CAEL-101 for the treatment…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Sep 21
Merck will obtain Acceleron's medicines for rare diseases, including its pulmonary arterial hypertension (PAH) drug sotatercept
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Sep 21
The US FDA approval is based on data from a large-scale clinical programme evaluating the efficacy, safety and…
29 Sep 21
The company will focus on the development of adjuvanted recombinant vaccine candidate, in partnership with GlaxoSmithKline (GSK)
28 Sep 21
EPIC-PEP study will enrol up to 2,660 healthy participants, aged 18 years and above, who live together with…
28 Sep 21
The regulatory approval is supported by data from two clinical trials, the Darvadstrocel-3002 study conducted in Japan, and…
27 Sep 21
Through the acquisition, Hikma will benefit from Custopharm’s 13 regulatory approved products, R&D professionals and a laboratory in…
27 Sep 21
The US regulatory agency approved Repatha based on results from HAUSER-RCT study, which showed a significant reduction in…
24 Sep 21
The collaboration is structured to optimise and validate VaxEquity’s saRNA platform and use it to advance novel therapeutic…
23 Sep 21
The US regulator authorised the third dose of Comirnaty based on review by its Vaccines and Related Biological…